More about

Hyperglycemia

News
October 17, 2024
1 min read
Save

Medtronic recalls MiniMed insulin pumps due to shorter-than-expected battery life

Medtronic recalls MiniMed insulin pumps due to shorter-than-expected battery life

Medtronic has issued an urgent medical device correction letter warning users of the MiniMed 600 and 700 series of insulin pumps of an increased risk for shorter-than-expected battery life, according to an FDA press release.

Clinical Guidance
Type 2 Diabetes
Pharmacologic Intervention

Dipeptidyl Peptidase-4

Steven V. Edelman, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Type 2 Diabetes
Treatment Guidelines

Treatment Algorithm

Steven V. Edelman, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Type 2 Diabetes
Pharmacologic Intervention

Overview of Pharmacologic Therapy

Steven V. Edelman, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Type 2 Diabetes
Complications

Acute Complications

Steven V. Edelman, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

Clinical Guidance
Type 2 Diabetes
Pharmacologic Intervention

Oral Agents

Steven V. Edelman, MD

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

News
June 28, 2024
8 min read
Save

Q&A: CGM ‘revolutionary’ for pregnant women with diabetes

Q&A: CGM ‘revolutionary’ for pregnant women with diabetes

Continuous glucose monitors have the potential to alleviate burdens, improve neonatal outcomes and predict disease progression for pregnant women with type 1, type 2 or gestational diabetes, according to two diabetes experts.

News
June 12, 2024
4 min read
Save

Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome

Relacorilant tied to sustained cardiometabolic improvements in Cushing’s syndrome

PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.

News
May 09, 2024
4 min read
Save

AI, new technology major focus at 2024 AACE annual meeting

AI, new technology major focus at 2024 AACE annual meeting

Looking to the future will be a key theme at the American Association of Clinical Endocrinology 2024 annual meeting with a keynote lecture focused on AI and sessions examining guidance updates and new technology.

News
April 22, 2024
2 min read
Save

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label portion of the GRACE phase 3 trial.

View more